SFA002

DRUG2 trials

Sponsors

SFA Therapeutics

Conditions

PsoriasisPsoriasis (PsO)

Phase 1

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques

RecruitingNCT05642182

SFA TherapeuticsPsoriasis

Start: 2022-03-31End: 2025-07-31Target: 90Updated: 2025-01-09

Phase 2

Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients

Not yet recruitingNCT06863493

SFA TherapeuticsPsoriasis (PsO)

Start: 2025-06-01End: 2026-09-01Target: 125Updated: 2025-03-11